



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company

CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2019-20

4th March, 2020

Online Filing at: listing.bseindia.com

To
The General Manager
DCS-CRD
BSE Ltd.
Dalal Street, Fort,
MUMBAI-400001

Script Code: **524470**

Subject: Intimation pursuant to the Regulation 30(2) of SEBI (LODR) Regulation, 2015 for adverse impact on the performance of the company.

Reference: Notification No. 50/2015-2020 Dated 3rd March, 2020 of Government of India, Ministry of Commerce & Trade, Department of DGFT.

Dear Sir/Ma'am

With reference to the above mentioned notification issued by the Government of India, we would like to inform to the Stock Exchange, Shareholders and General Investors of the company; that the company is dealing in the export of Pharmaceuticals formulation and drugs manufactured by some of the restricted drugs being used in formulations thereof, which has been restricted by the Government of India with immediate effect till the further orders, by way of the aforesaid notification.

The management considered that the aforesaid restrictions will cause the adverse impact on the company's performance and financials results to that extent in the coming period.


Therefore, the management has considered that the matter is a Price Sensitive Information and being disclosed to the Stock Exchange as per requirement of the Regulation 30(2) of the SEBI (LODR) Regulations, 2015.

This is for General Information for the stakeholders at large.

You are requested to please take on record the same in your records and reference.

Thanking you,
Yours faithfully,

FOR, SYNCOM FORMULATIONS (INDIA) LIMITED


KEDARMAL SHANKARLAL BANKDA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 00023050



Bringing a smile on every face...